# Implementation of a Pediatric Oncology Precision Medicine Clinic to Personalize Approaches for Diagnosing and Treating Solid Tumors

**Authors:** Madeline Keane, Natalia Wojciechowska, Lindsay Zumwalt, Emilie Sandfeld, Alejandra Dominguez, Jason Wang, Anish Ray

PMC · DOI: 10.32604/or.2025.065547 · Oncology Research · 2025-07-18

## TL;DR

This paper describes the creation and impact of a Pediatric Oncology Precision Medicine Clinic that uses genetic sequencing to guide personalized cancer treatment.

## Contribution

The paper introduces a scalable model for a Precision Medicine Clinic in pediatric oncology, enabling targeted treatment based on genetic data.

## Key findings

- The clinic identified 133 genetic variants across 101 genes in 69 pediatric cancer patients.
- Four patients received targeted therapy based on the clinic's recommendations.
- The clinic provides a framework for implementing precision medicine in pediatric oncology.

## Abstract

Precision medicine is an emerging approach for treating pediatric cancer due to its ability to target tumor-specific genetic drivers rather than provide broad and aggressive treatments. The study aimed to outline the establishment and impact of a Precision Medicine Clinic (PMC) in the setting of pediatric oncology, with the objective of offering targeted treatment options within the institution and creating a scalable model for adoption by other healthcare systems to achieve a wider impact.

Recognizing this need for an individualized approach to treating patients, Cook Children’s Medical Center (CCMC) established a multidisciplinary molecular tumor board in 2019, followed by the launch of an official PMC in 2021. Before this, there was no dedicated place to discuss and evaluate genetic sequencing results.

In 2022 and 2023, the PMC discussed 69 patients with a wide variety of oncologic diagnoses. Through the clinic’s efforts, 133 genetic variants across 101 genes have been identified, spanning oncogenic pathways related to cell cycling, DNA processing, and cell signaling. Of the sequenced patients, four have received targeted therapy according to recommendations from the PMC.

While the PMC continues to evaluate patients and their long-term outcomes, the continually growing PMC at CCMC represents the beginning of the advancement of treating pediatric oncology patients through the interpretation of genetic sequencing results, making actionable targeted treatment recommendations, and continuing to follow the patient’s course of care over time. This additionally provides a framework for starting a PMC that can be adapted for specific clinical needs and implemented broadly.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** Solid Tumors (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12308242/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12308242/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12308242/full.md

---
Source: https://tomesphere.com/paper/PMC12308242